Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

Francesca Palandri; Ilaria Iacobucci; Fabrizio Quarantelli; Fausto Castagnetti; Daniela Cilloni; Michele Baccarani; GIMEMA Working Party on CML

doi:10.3324/haematol.12033

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

Haematologica. 2007 Nov;92(11):1579-80. doi: 10.3324/haematol.12033.

Authors

Francesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, Fausto Castagnetti, Daniela Cilloni, Michele Baccarani; GIMEMA Working Party on CML

PMID: 18024412
DOI: 10.3324/haematol.12033

Abstract

CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response (MolR) of 54 early chronic phase (ECP) and of 115 late CP patients who achieved a stable CCgR with IM 400 mg/daily. ECP patients obtained earlier, higher and more sustained MMolR.

Publication types

Clinical Trial, Phase II
Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides
Cytogenetics
Disease-Free Survival
Humans
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / diagnosis
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Piperazines / administration & dosage*
Pyrimidines / administration & dosage*
Time Factors

Substances

Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate